Canadian Securities Exchange Welcomes Listing of DiagnosTear Technologies Inc
Canadian Securities Exchange Welcomes Listing of DiagnosTear Technologies Inc
Toronto, Ontario--(Newsfile Corp. - December 9, 2024) - The Canadian Securities Exchange ("CSE" or "the Exchange") today welcomed the listing of DiagnosTear Technologies Inc. ("DiagnosTear" or the "Company"). The Israel-based ophthalmic company recently completed an offering of subscription receipts, which converted into common shares and warrants prior to listing on the CSE. Its common shares were listed on the CSE today under the symbol DTR.
安大略省多伦多--(Newsfile Corp.,2024年12月9日)——加拿大证券交易所(“CSE” 或 “交易所”)今天对Diagnostear Technologies Inc.(“DiagnostEAR” 或 “公司”)的上市表示欢迎。这家总部位于以色列的眼科公司最近完成了认购收据的发行,在CSE上市之前,认购收据转换为普通股和认股权证。其普通股今天在CSE上市,股票代码为DTR。
DiagnosTear is focused on the development and commercialization of disruptive diagnostic solutions for better management of eye diseases. The Company's TeaRx technology is a diagnostic platform intended for rapid, point-of-care testing of ophthalmic pathologies through tear fluid. The Company is currently developing products for the diagnosis of Dry Eye Disease and Red Eye causes.
DiagnostEAR专注于颠覆性诊断解决方案的开发和商业化,以更好地管理眼部疾病。该公司的TearX技术是一个诊断平台,旨在通过泪液对眼科疾病进行快速的即时检测。该公司目前正在开发用于诊断干眼病和红眼病因的产品。
"The CSE has established itself as an ideal exchange for emerging companies advancing innovative technologies," said James Black, the CSE's Vice President, Listings Development. "We welcome DiagnosTear to the Exchange and wish the Company well with its exciting product development program."
CSE上市开发副总裁詹姆斯·布莱克表示:“CSE已成为新兴公司推进创新技术的理想交易所。”“我们欢迎DiagnostEAR加入交易所,并祝愿公司令人兴奋的产品开发计划一切顺利。”
"We are excited about the commencement of trading on the CSE," said Yaacov Michlin, DiagnosTear's Chairman of the Board. "Building on our unique expertise in multi-parametric analysis of tear fluid, our efforts are focused on becoming a global leader in the development and commercialization of point-of-care diagnostic tools for ocular diseases like dry eye and red eye."
DiagnostEAR董事会主席雅科夫·米奇林说:“我们对CSE的开始交易感到兴奋。”“基于我们在泪液多参数分析方面的独特专业知识,我们的努力重点是成为干眼和红眼等眼部疾病的即时诊断工具开发和商业化的全球领导者。”
Dr. Shimon Gross, DiagnosTear's CEO, added: "Our solutions are non invasive, simple to perform and to interpret, and intended to allow healthcare providers to target the underlying cause of the disease and provide personalized treatment options."
DiagnostEAR首席执行官西蒙·格罗斯博士补充说:“我们的解决方案是非侵入性的,易于执行和解释,旨在使医疗保健提供者能够针对疾病的根本原因并提供个性化的治疗选择。”
About the Canadian Securities Exchange:
关于加拿大证券交易所:
The Canadian Securities Exchange is a rapidly growing exchange invested in working with entrepreneurs, innovators and disruptors to access public capital markets in Canada. The Exchange's efficient operating model, advanced technology and competitive fee structure help its listed issuers of all sectors and sizes minimize their cost of capital and enhance global liquidity.
加拿大证券交易所是一家快速发展的交易所,致力于与企业家、创新者和颠覆者合作,以进入加拿大的公共资本市场。交易所高效的运营模式、先进的技术和有竞争力的费用结构有助于其所有行业和规模的上市发行人最大限度地降低资本成本并增强全球流动性。
Our client-centric approach and corresponding products and services ensure businesses have the support they need to confidently realize their vision.
我们以客户为中心的方法以及相应的产品和服务确保企业获得所需的支持,以自信地实现其愿景。
The CSE offers global investors access to an innovative collection of growing and mature companies.
CSE为全球投资者提供了进入一系列成长型和成熟公司的创新机会。
STAY CONNECTED WITH THE CSE
=============================
Website:
Blog:
CSE TV on YouTube:
CSE's "The Exchange for Entrepreneurs" Podcast:
Linkedin:
Twitter:
Instagram:
Facebook:
与案例保持联系
=============================
网站:
博客:
YouTube 上的 CSE 电视:
CSE 的 “企业家交易所” 播客:
领英:
推特:
Instagram
脸书:
Contact:
James Black
416-572-2000
james.black@thecse.com
联系人:
詹姆斯·布莱克
416-572-2000
james.black@thecse.com
译文内容由第三方软件翻译。